A B S T R A C T Tangier disease is a rare familial disorder characterized by enlarged orange tonsils, transient peripheral neuropathy, hepatosplenomegaly, and lymphadenopathy, as well as striking reductions in plasma high density lipoproteins (HDL) and their major protein constituents, apolipoproteins (apo)A-I and A-II. In order to test the hypothesis that Tangier patients have abnormal apoA-I or apoA-II, the in vitro lipoprotein binding and in vivo metabolic characteristics of these proteins isolated from normal and Tangier plasma, were studied in normal subjects and patients with Tangier disease.
A B S T R A C T Tangier disease is a rare familial disorder characterized by enlarged orange tonsils, transient peripheral neuropathy, hepatosplenomegaly, and lymphadenopathy, as well as striking reductions in plasma high density lipoproteins (HDL) and their major protein constituents, apolipoproteins (apo)A-I and A-II. In order to test the hypothesis that Tangier patients have abnormal apoA-I or apoA-II, the in vitro lipoprotein binding and in vivo metabolic characteristics of these proteins isolated from normal and Tangier plasma, were studied in normal subjects and patients with Tangier disease.
After incubation with normal plasma, significantly greater percentages of radiolabeled Tangier apoA-I were associated with the 1.063-g/ml supernate (6%) and the 1.21 g/ml infranate (19%), and a lower percentage with HDL (75%), than those observed for normal apoA-I (2, 8, and 90%, respectively). In contrast, the lipoprotein binding properties of normal and Tangier apoA-II were very similar. Following the injection of radiolabeled normal and Tangier apoA-I into normal subjects (n = 4), the mean residence times of the specific activity for apoA-ITangier were significantly lower, both in plasma (1.29 d) and in HDL (1.34 d), than those observed for normal apoA-I (3.80 and 4.06 d). In Tangier homozygotes the decay rates of these tracers were very rapid and were similar. No significant differences between the kinetics of normal and Tangier apoA-II were observed in normal subjects (n = 2).
Tangier homozygotes (n = 3) had mean plasma Received for publication 28 December 1981, and in revised form 20 July 1982.
HDL cholesterol, apoA-I, and apoA-II concentrations that were 4, 2, and 11% of normal (n = 24), respectively, whereas for heterozygotes (n = 3) these values were 46, 62, and 68% of normal. In homozygotes, in contrast to normals or heterozygotes, a significant fraction of both apoA-I and apoA-II were found in the 1.063-g/ml supernate instead of in HDL. Homozygotes had apoA-ITangier synthesis rates and residence times that were 41 and 5% of values observed for normal apoA-I in normal subjects, and for apoA-II in homozygotes, these parameters were 63 and 18% of normal. Heterozygotes had apoA-I synthesis rates and residence times that were 92 and 66% of normal, and for apoA-II these values were 101 and 64% of normal.
These data are consistent with the concept that apoA-ITangier is functionally and metabolically distinct from normal apoA-I, and is the cause of the striking hypercatabolism of apoA-I and apoA-II, and the lipoprotein abnormalities observed in Tangier disease.
INTRODUCTION
Tangier disease was described by Fredrickson et al. (1) in two young siblings from Tangier Island in the Chesapeake Bay. These children presented with enlarged, orange tonsils, mild hepatosplenomegaly, and lymphadenopathy, and subsequently developed mild transient peripheral neuropathy (1) (2) (3) (4) (5) . Cholesterol-ester laden reticuloendothelial cells have been noted in the bone marrow, tonsils, skin, rectal mucosa, liver, spleen, lymph nodes, and conjunctiva of these patients (1, (5) (6) (7) (8) . A striking deficiency of high density lipoprotein (HDL)' constituents was found in these subjects (2) (3) (4) . The parents of these patients did not share their clinical features, but did have HDL levels that were -50% of normal, and therefore were designated as obligate heterozygotes for this autosomal recessive disorder (2) (3) (4) . HDL, as isolated from human plasma by ultracentrifugation in the density range of 1.063 to 1.21 g/ml, consist (weight percent) of -50% protein, 25% phospholipid, 20% cholesterol, and 5% triglyceride (9-10). The cholesterol component of HDL has been shown to be inversely correlated with coronary artery disease incidence (11) (12) (13) (14) . The major protein constituents of HDL are apolipoproteins (apo) A-I and A-Il (9, 15, 16) , which generally consitute >90% of the protein mass of HDL. Tangier homozygotes have plasma HDL cholesterol and apoA-II levels that are -5-10% of normal, and apoA-I concentrations that are 1-2% of normal (17) (18) (19) . Not only do Tangier homozygotes have markedly decreased apoA-I and apoA-II concentrations, but the distribution of these apolipoproteins among plasma lipoproteins is abnormal. In normal plasma 90% or more of the mass of each of these apolipoproteins is found within the HDL density region of 1.063-1.21 g/ml (20) (21) (22) ; whereas in Tangier plasma, -80% of apoA-II and 30% of apoA-I mass is in the 1.063 g/ml supernate, and -70% or more of apoA-I is in 1.21 g/ml infranate (19) .
Tangier homozygotes also have decreased low density lipoprotein (LDL) levels, hypocholesterolemia, hypertriglyceridemia, increased very low density lipoprotein (VLDL) concentrations, and fasting chylomicronemia (1) (2) (3) (4) 23) . It has been suggested that the lipid deposition in homozygotes is due to the uptake of abnormal triglyceride-rich lipoproteins by macrophages (3, 5, 24) . Human lymph chylomicrons contain significant amounts of apoA-I and apoA-II, and these can serve as precursors for plasma HDL apoA-I and apoA-II (25) . This conversion process appears to be defective in Tangier homozygotes (26) , resulting in rapid and altered apoA-I and apoA-II fractional catabolism, both under steady-state base-line conditions (19) , and after HDL infusion (27, 28) .
The purpose of this study was to define the lipoprotein binding properties and metabolic characteristics of apoA-I and apoA-II, as isolated from both normal and Tangier plasma, in normal subjects as well as Tangier heterozygotes and homozygotes. These investigations were carried out in order to test the hypothesis that Tangier apoA-I and apoA-II are functionally and metabolically abnormal apolipoproteins. The data presented here are consistent with the concept that Tangier apoA-I is functionally and kinetically abnormal, and that the clinical features and lipoprotein abnormalities observed in Tangier disease are due to this abnormal apoA-I (apoA-ITangjer).
METHODS
Subjects studied. The age, sex, height, weight, plasma lipid, and lipoprotein cholesterol values for the subjects studied are given in Table I . Mean values (±SD) are given for weights and plasma cholesterol and triglyceride concentrations. Weights were determined daily during the course of each study on a metabolic balance, and plasma lipids were measured on all blood samples obtained during the course of each metabolic study. Informed consent was obtained from all subjects, and all studies were performed on a metabolic ward. All subjects had normal hepatic, renal, and thyroid function, and were studied while on an isocaloric, 16 and all samples from homozygotes were run undiluted. Standard curves for apoA-I were linear over a concentration range from 0.25 to 16.0 mg/dl and for apoA-II over a range from 0.5 to 10.0 mg/dl. Samples from homozygotes were also run on electroimmunoassay apoA-I and apoA-II, and these results gave very good agreement to those obtained by radial immunodiffusion (20, 28) .
ApoA-I and apoA-II were isolated by column chromatography from HDL (1.09-1.21 g/ml) as previously described (37, 38) . ApoA-I was isolated from Tangier plasma (patient 1) from the 1.21-g/ml supernate by preparative sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (0.1% SDS, 15% acrylamide, 0.05% bis, 0.552% cross linkage [39] ). The SDS was subsequently removed from the protein by electrophoresis, using an ISCO Electrophoretic Sample Concentrator, model 750 (Instrumentation Specialties Co., Lincoln, NE). ApoA-I was isolated from normal plasma in identical fashion for purposes of comparison with Tangier ApoA-I. ApoA-II was isolated from Tangier plasma (patient 1) from the 1.21-g/ml supernate by column chromatography (38) . ApoA-II was also isolated from normal plasma in identical fashion for purposes of comparison.
Radioiodination of apolipoproteins. All apoA-I and apoA-II preparations used for radioiodination formed discrete bounds on SDS PAGE (40) . Apolipoproteins formed a line of immunoprecipitation only against their own respective antisera when tested with antisera for apoA-I, apoA-II, apoB, apoC-II, apoC-III, apoE, and albumin. ApoA-I and apoA-II were iodinated with '251 or 13'I (New England Nu- clear, Boston, MA) at a mean protein concentration of 3.6±1.1 mg/ml in sterile 1 M glycine, 0.1 M Tris, pH 8.5 buffer, by the iodine monochloride method of McFarlane (39) . For Radiolabeled preparations were subjected to SDS PAGE with unlabeled apo standard to ascertain the location of radioactivity on PAGE. All preparations were diluted 1:10 with sterile 5% human albumin solution to minimize radiation damage, were subjected to Millipore (Millipore Corp., Bedford, MA) filtration (0.22 micron filter), and tested for pyrogenicity and sterility before use. For single isotope studies a mean of 84±7 MCi of 125I were used, and for double isotope studies a mean of 87±5 of 1251 and 23±9 MCi of 13 1 were injected intravenously. A mean of 0.2±0.1 mg of labeled apoprotein in a mean volume of 0.8±0.3 ml were injected intravenously in tracer studies. Radiolabeled HDL was isolated and labeled with 1251 as previously described (19) .
Metabolic studies. 26 normal male and female subjects, 3 Tangier heterozygotes, and 3 Tangier homozygotes were studied. Six normal male subjects, eight normal female subjects, one heterozygote and all three homozygotes simultaneously received normal radiolabeled apoA-I and apoA-II. Three normal males and one normal female subject received normal radiolabeled apoA-I only, and two normal males received normal radiolabeled apoA-II only. One normal male, three normal females, and two Tangier homozygotes (patients 2 and 3) simultaneously received 1251 Tangier apoA-I and 1511 normal apoA-I. One normal male and one normal female subject simultaneously received 125I Tangier apoA-II and 131I normal apoA-II. Tracer studies in normal subjects and heterozygotes were of 13-21 d duration (in most cases 14 d) and in Tangier homozygotes were of 7 d duration. Radiolabeled autologous HDL studies in eight normal controls, and two heterozygotes were performed as previously described (19) .
In all metabolic studies blood was obtained in 0.1% EDTA just before injection of radioactivity, at 10 min, 6 h, and 12 h after injection, and then daily for the duration of the study. In homozygotes blood samples were also obtained 3 and 6 h after injection. Plasma was separated from blood at 4°C in a refrigerated centrifuge. HDL (1.063-1.21 g/ml) was isolated as previously described from plasma obtained just before injection, and at 6 h, 12 h, and days 1, 4, 7, 10, and 13, or 14 after injection. In homozygotes HDL was also isolated at 3 and 9 h after injection, but not on days 10, 13, or 14. Radioactivity in plasma, 1.063 g/ml supernate, HDL, and 1.21 g/ml infranate was determined utilizing a Packard model 5260 Autogamma Counter Spectrometer.
Lipoprotein binding studies and column chromatography. Radiolabeled apo (1-2 Ml) were incubated with 5-ml aliquots of plasma (normal or Tangier plasma) for 30 min at 37°C in a shaking water bath. Aliquots were subjected to ultracentrifugation for the isolation of HDL (1.063-1.21 g/ ml) as previously described. In addition 5-ml plasma aliquots were subjected to gel permeation chromatography with 100 X 1.2 cm columns (Kontes Glass Co., Vineland, NJ) of Sepharose 6B-C1 (Pharmacia Fine Chemicals, Div. Pharmacia, Inc., Piscataway, NJ) in 0.85% NaCl, 0.01% EDTA, 1 mM sodium azide, pH 7.4 buffer at room temperature (24°C). Sample volumes applied to the column were 5 ml and flow rates were~-15 ml/h. Preparations Characterization of radioiodinated apolipoproteins. The mean efficiencies of iodination for normal apoA-I and apoA-II preparations were 53.6±7.1% and 62.4±9.2%, respectively, and for Tangier apoA-I and apoA-II preparations were 39.2±1.1% and 73.5±0.9%, respectively. Assuming a molecular weight of 28,000 for apoA-I, and 18,000 for apoA-II, a mean of 0.6±0.2 mol of iodine/mol of protein was incorporated into normal apoA-I during iodination, and for normal apoA-II 0.9±0.1. For Tangier apoA-I and apoA-II these values were 0.5±0.1 and 0.9±0.1, respectively. All radioiodinated apo preparations contained no free iodine by radiochromatography, and <1% by TCA precipitation, and were sterile and pyrogen-free.
The distributions of apoA-I and apoA-II radioactivity among plasma lipoproteins for both normal and Tangier plasma after ultracentrifugation are shown in Defective Metabolism of ApoA-ITangier Mean values±SD, represents the mean of seven HDL (d 1.063-1.21 g/ml) isolations from fasting normal and Tangier heterozygotes, and four HDL (d 1.063-1.21 g/ml) isolations in homozygotes. Values in parenthesis indicate the fraction of total for each subject. The kinetics of radiolabeled normal and Tangier apoA-I or normal and Tangier apoA-H1 were studied in normal control subjects. Table III . The data is given for in vivo plasma samples (10 min after injection). In vitro distributions were very similar to in vivo results in all cases. No significant change in the distributions of radioactivity among lipoprotein fractions was noted throughout the course of any study. A significantly (P < 0.01) higher percentage of Tangier apoA-I radioactivity was associated with the 1.063-g/ml supernate and the 1.21-g/ml infranate than that seen for normal apoA-I radioactivity in normal plasma. Such differences were not observed for Tangier plasma; however much higher percentages of both normal and Tangier apoA-I radioactivity were associated with both the 1.063-g/ml supernate and the 1.21-g/ml infranate than tha't observed in normal plasma. The distributions of normal and Tangier apoA-II radioactivity among normal plasma lipoproteins were very similar. Similar'data were obtained when normal and Tangier radiolabeled apoA-I and apoA-II were incubated with plasma (30'min, 37°C), and then subjected to Sepharose 6B column chromatography. When normal and Tangier radiolabeled apoA-I and apoA-II along with unlabeled apoprotein standard were run on SDS PAGE, >90% of the radioactivity could be recovered in the appropriate gel band.
Apolipoprotein metabolic, parameters. Apo A-I and A-II metabolic parameters are shown in Table IV . Normal female subjects had significantly (P < 0.01) higher apoA-I levels and slightly higher apoA-II levels than did males. Normal female subjects had significantly (P <'0.05) higher apoA-I and apoA-II synthesis rates than did normal males. In paired studies in normal subjects (n = 14) the mean (4.46±1.04 d) apoA-I plasma residence time was significantly (P < 0.01) shorter than that of apoA-II (4.97±1.06 d). Similar data were obtained following the injection of autologous radiolabeled HDL in eight normal subjects (19) . In these studies the mean (±SD) apoA-I specific activity residence time within HDL (4.24±0.51 d) was significantly (P < 0.01) lower than that of apoA-11 (4.83+0.75 d). The methodology and details of these studies have been previously reported (19) but the apoA-I and apoA-II specific activity within HDL were never assessed by multiexponential curve fitting techniques.
Het'erozygotes had apoA-I and apoA-II plasma levels that were significantly lower than normal (see Table  IV ). In normal subjects and heterozygotes =90% of both plasma apoA-I and apoA-II were found within the HDL (d 1.063-1.21 g/ml) density region. Heterozygotes, who received either radiolabeled HDL or apo had decreased apoA-I and apoA-II residence times, with relatively normal synthesis rates.
Tangier homozygotes had significantly lower plasma apoA-I and apoA-II concentrations than did normal subjects. A mean of 32.4±3.1% of plasma apoA-I mass and 83.5±5.7% of plasma apoA-II mass were associated with the 1.063-g/ml supernate fraction in homozygotes (n = 3), similar to' the distribution noted for radiolabeled apoA-I and apoA-II (see Table III ). After the injection of normal radiolabeled apoA-I and apoA-II into homozygotes (n = 3), the specific activity decay of these tracers was significantly faster than that seen * Mean values based on in vivo plasma obtained 10 min after injection of tracers. 1.063 top is the 1.063-g/ml 1.063-1.21-g/ml fraction, and the 1.21B is the 1.21-g/ml infranate. I Significantly (P < 0.01) different from normal apoA-I radioactivity (t test analysis).
in normal subjects, and as in normals, apoA-I was degraded at a faster rate than apoA-II (see Fig. 1 ). Not only did Tangier homozygotes have enhanced fractional catabolism of apoA-I and apoA-II, but apoA-I and apoA-II synthesis was somewhat reduced in them as well (Table IV) . When normal and Tangier radiolabeled apoA-I were injected into normal subjects, the specific radioactivity decay in both plasma and HDL was significantly faster for the Tangier apoA-I than for normal apoA-I, as shown in Fig. 2 and Table V. However in Tangier homozygotes the specific radioactivity decay of these two tracers in both plasma and the 1.063-g/ml supernate was similar (see Fig. 3 and Table V) . Therefore, supernate, HDL is the kinetic parameters in homozygotes were very similar regardless of which tracer was used. After the injection of normal and Tangier radiolabeled apoA-II, no significant difference in specific radioactivity decay of these two tracers was noted in either plasma or HDL in two normal subjects (see Fig. 4 and Table V) . Tables I and II, Heterozygotes 1 and 2 had radiolabeled HDL studies and other subjects had radiolabeled apolipoprotein studies. Homozygotes 1-3 were studied with normal radiolabeled apoA-I and apoA-II, while homozygotes 2 and 3 were also studied with radiolabeled apoA-ITangier (study b). Mean ApoA-I parameters in Tangier homozygotes are reported for apoA-ITang,.r studies only. Mean values are given ±SD.
I Significantly (P < 0.01) different from normal.
( 1-4, 18, 19) . The striking reductions in plasma apoA-I and apoA-II as observed in homozygotes are consistent with previous studies (17-19, 27, 28, 43) . Homozygotes do not appear to have significant deficiencies of other apolipoproteins (43) . The only HDL constituent not greatly reduced in homozygotes was HDL triglyceride. Tangier heterozygotes had normal LDL levels, moderate increases in VLDL, and reduced HDL levels as previously reported (2) (3) (4) .
Radiolabeled normal apoA-I and apoA-II radioactivity was found mainly in the HDL density region after injection of these tracers into normal subjects.
Ultracentrifugation and column chromatography data were in good agreement. The distribution of these tracers among plasma lipoproteins was very similar to the mass distribution of apoA-I and apoA-II, consistent with the concept that these apolipoproteins can readily exchange among plasma lipoproteins (10, 44) . When normal radiolabeled apoA-I and apoA-II were injected into Tangier homozygotes, -80% of apoA-II radioactivity and 30% of apoA-I radioactivity were associated with the 1.063-g/ml supernate, and -50% of apoA-I radioactivity was found in the 1.21-g/ml infranate; also consistent with the mass distribution of (19) , and after HDL infusion (27, 28) . This rapid catabolism was seen in both whole plasma and -the 1.063-g/ml infranate. Our In normal subjects the specific radioactivity decay right panel) in a normal of Tangier apoA-I was significantly faster than that of zygotes (0, 0, A).
normal apoA-I in both plasma and HDL. Recent observations from our laboratory have demonstrated that plasma noted in these Tangier apoA-I has a slightly higher molecular weight sly (19, 28) . Tangier on SDS PAGE, greater isoform heterogeneity, and dif-:n among plasma li-ferent amino acid composition than normal apoA-I, Tangier plasma was whereas Tangier and normal apoA-II were virtually h normal radiolabeled identical in these respects (45) . Zannis et al. (46) have normal and Tangier recently reported that, on two dimensional gel elecrangier apoA-I radio-trophoresis of plasma, Tangier homozygotes have in-3-g/ml supernate and creased proportions of the plasma apoA-I isoforms rmal plasma) as com-apoA-I2 and apoA-13, considered to be precursor apoAse data are consistent I isoforms (47), while normal subjects have mainly apoA-14 and apoA-15 in their plasma (46) . When we have run two dimensional gel electrophoresis on plasma obtained from the three Tangier homozygotes studied in this report we have observed a similar pattern as that reported by Zannis et al. (46) . However, the Tangier apoA-I used in our metabolic studies was isolated from the 1.21-g/ml supernate (i.e., the lipoprotein fraction) following ultracentrifugation of Tan gier plasma. This Tangier apoA-I preparation contained apoA-I4 and apoA-I5 as its major isoforms, similar to normal apoA-I (45) . These data suggest that ultracentrifugation may selectively remove apoA-12 and apoA-13 from plasma lipoproteins especially at low apoA-I and HDL concentrations. We cannot exclude the possibility that the in vivo kinetic differences observed between apoA-ITangier and normal apoA-I may be due to differences in the radioiodination of the various apoA-I isoforms. Additional research is required to precisely determine the nature of the differences between the apoA-I isoforms in normal and Tangier plasma, and to elucidate the exact defect in Tangier apoA-I.
The data are consistent with the concept that Tangier apoA-I is structurally and metabolically different from normal apoA-I, and we therefore have designated this apolipoprotein as apoA-ITangier. In homozygotes the specific activity decay of normal and apoA-ITangier were similar, possibly because the normal apoA-I associated with abnormal lipoproteins, containing apoA-ITangier.
Early work by Lux et al. (48) suggested that Tangier homozygotes had abnormal HDL constituents, but these workers were unable to detect any significant differences in the amino acid composition between normal and Tangier apoA-I, possibly because the apoA-I amino acid sequence was not known at that time. In contrast to apoA-ITangier, our data indicate that Tangier apoA-II appears to be functionally and metabolically identical to normal apoA-II. Both amino acid compositional data (45) as well as the kinetic studies with normal and Tangier apoA-II support this view.
In our view the abnormal apoA-I found in Tangier homozygotes results in the formation of abnormal apoA-I and apoA-II containing lipoproteins as found in the chylomicron, VLDL, LDL, and HDL density regions (17-19, 23-28, 49) . These particles may arise not because of the inability of apoA-ITangier to bind to lipid, but possibly because lipoproteins containing this apolipoprotein are not normally catabolized and are rapidly cleared from the circulation by reticuloendothelial cells (5, 19, 24) . These alterations result in cholesterol ester deposition in these cells, striking hypercatabolism of apoA-I and apoA-II, and a marked deficiency of HDL. The data presented are consistent with the concepts that the lipoprotein abnormalities seen in Tangier disease are due to an abnormal apoA-I (apoA-IT.ngier), and that normal apoA-I is essential for HDL formation (50). 
